Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment.
10.15279/kpba.2017.22.3.141
- Author:
Hyung Chang KANG
1
;
Ji Kon RYU
;
Sang Hyub LEE
;
Yong Tae KIM
Author Information
1. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. jkryu@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Pancreas;
Neuroendocrine tumors;
Neoplasms;
Metastasis
- MeSH:
Disease Progression;
Female;
Humans;
Liver;
Middle Aged;
Molecular Targeted Therapy;
Neoplasm Metastasis;
Neuroendocrine Tumors*;
Pancreas;
Pancreaticoduodenectomy
- From:Korean Journal of Pancreas and Biliary Tract
2017;22(3):141-146
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A 46-year-old female with abnormal radiologic finding was diagnosed with pancreatic neuroendocrine tumor and multiple hepatic metastasis. Molecular targeted therapy (everolimus) and two times of transarterial chemoembolizations (TACE) were performed before pylorus-preserving pancreaticoduodenectomy (PPPD). After 2nd TACE and PPPD, grade 2 pancreatic neuroendocrine tumor was pathologically confirmed. Four times of additional TACE was done. After size increase of several probable hepatic metastasis in the both lobes of liver, laparoscopic left lateral sectionectomy of liver was performed. After two and half years of left lateral sectionectomy, 7th TACE was performed and the patients have survived without further disease progression. This case suggests that patients with pancreatic neuroendocrine tumor and hepatic metastasis can be treated by TACE, primary tumor resection, surgery for liver metastasis and molecular targeted therapy. Therefore, aggressive multidisciplinary approaches need to be considered for long term survival of patients with pancreatic neuroendocrine tumor with hepatic metastasis.
